Petra Reinke
Charité
401 Papers
2.5K Citations
Petra Reinke is an academic researcher from Charité. The author has contributed to research in topics: Transplantation & Medicine. The author has an hindex of 64, co-authored 386 publications. Previous affiliations of Petra Reinke include Paracelsus Private Medical University of Salzburg & Center for Cell and Gene Therapy.
Chat about Author
Papers
Human cytomegalovirus reactivation in bone-marrow-derived granulocyte/monocyte progenitor cells and mature monocytes.
TL;DR: At least three independent mechanisms of virus reactivation are discussed: systemic inflammation connected with strong tumor necrosis factor alpha release; application of cAMP-elevating drugs, and highly stressful events associated with increased plasma catecholamine levels.
HLA type-independent generation of antigen-specific T cells for adoptive immunotherapy.
Markus H. Hammer,Sonja Meyer,G. Brestrich,Andreas Moosmann,Florian Kern,Lydia Tesfa,Nina Babel,Alexa Mittenzweig,Cliona M. Rooney,Wolfgang Hammerschmidt,Hans-Dieter Volk,Petra Reinke +11 more
TL;DR: The protocol combines the biosafety of peptide‐based approaches with HLA type independence and may help to advance adoptive immunotherapy in the future.
Interleukin-6 serum level assessment using a new qualitative point-of-care test in sepsis: A comparison with ELISA measurements.
Joerg C. Schefold,Dietrich Hasper,Stephan von Haehling,Christian Meisel,Petra Reinke,Hans-Georg Schlosser +5 more
TL;DR: Significant correlations of IL-6 levels determined using a POC test and semiautomatic ELISA are demonstrated, demonstrating a new tool that may help to initiate early goal-directed therapy.
Toward an Optimized Process for Clinical Manufacturing of CAR-Treg Cell Therapy
TL;DR: Current progress in the field of CAR technology and its application to regulatory T cells is reviewed and ways to improve current CAR-Treg manufacturing processes are recommended based on lessons learned from first-generation Treg therapeutics as well as from anticancerCAR-T cell development.
Enzyme-linked immunosorbent spot assay for donor-reactive interferon-gamma-producing cells identifies T-cell presensitization and correlates with graft function at 6 and 12 months in renal-transplant recipients.
Peter Nickel,Franziska Presber,Gantuja Bold,Didier Biti,Constanze Schönemann,Stefan G. Tullius,Hans-Dieter Volk,Petra Reinke +7 more
TL;DR: The pretransplant ELISPOT assay might be useful to identify T-cell presensitized patients, who are at heightened risk for severe early acute rejection, and an analysis of ELisPOT donor-reactive cells during the early posttransplant period might allow an identification of patients at risk for immune-mediated graft deterioration.